Determination of the elimination half-life of fibroblast growth factor-23.

CONTEXT Tumor-induced osteomalacia (TIO) is a rare paraneoplastic disease caused by mesenchymal tumors that secrete fibroblast growth factor-23 (FGF-23), a newly-described vitamin D and phosphate-regulating hormone. Surgical removal of the tumor, the ectopic source of circulating FGF-23, offers the opportunity to determine the elimination half-life of FGF-23. OBJECTIVE The aim of the study was to determine the elimination half-life of FGF-23. PATIENTS/METHODS The tumors were removed from three patients with TIO, and serum samples were taken every 30 min for up to 72 h after the operation. FGF-23 was measured by both a C-terminal/intact assay and an intact assay, and the elimination half-life was determined by one phase exponential decay methodology. SETTING The Mark O. Hatfield Clinical Research Center of the National Institutes of Health, a tertiary referral clinical research center, was the setting for the study. RESULTS The elimination life of FGF-23 as determined by C-terminal/intact and intact assays was 46 +/- 12 and 58 +/- 34 min, respectively. CONCLUSIONS The plasma half-life of serum FGF-23 is in the range of 46-58 min.

[1]  R. Kumar,et al.  Tumor-induced osteomalacia and the regulation of phosphate homeostasis. , 2000, Bone.

[2]  T. Clemens,et al.  Tumor‐Induced Osteomalacia: Clinical and Basic Studies , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  D. Miao,et al.  Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. , 2004, Endocrinology.

[4]  M. Razzaque,et al.  Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. , 2006, The American journal of pathology.

[5]  M. Wolf,et al.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[6]  M. Razzaque,et al.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[7]  P. Kao,et al.  Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. , 1994, The New England journal of medicine.

[8]  K. Miyamoto,et al.  Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 Production* , 2003, The Journal of Biological Chemistry.

[9]  D. Morgan,et al.  The assessment of phosphate reabsorption. , 1969, Clinica chimica acta; international journal of clinical chemistry.

[10]  M. Wolf,et al.  Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? , 2006, Kidney international.

[11]  T. Strom,et al.  Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis , 2006, Journal of Biological Chemistry.

[12]  S. Takeda,et al.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Kato,et al.  Circulating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo* , 2005, Journal of Biological Chemistry.

[14]  K. White,et al.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. , 2003, The Journal of clinical investigation.

[15]  D. Behar,et al.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis , 2004, Nature Genetics.

[16]  J. Dennis,et al.  Protein glycosylation in development and disease , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[17]  Y. Takeuchi,et al.  FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  L. Weinstein,et al.  Fibroblast Growth Factor‐23 Is Regulated by 1α,25‐Dihydroxyvitamin D , 2005 .

[19]  R. Kumar,et al.  Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral Metabolism , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  Kozo Nakamura,et al.  Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. , 2004, The Journal of clinical endocrinology and metabolism.

[21]  M. Drezner.  Tumor-Induced Osteomalacia , 2001, Reviews in Endocrine and Metabolic Disorders.

[22]  Y. Takeuchi,et al.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.

[23]  R. Mason,et al.  Bone as a source of FGF23: regulation by phosphate? , 2004, Bone.

[24]  K. White,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[25]  Y. Takeuchi,et al.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.

[26]  T. Spector,et al.  The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate Wasting , 2001 .

[27]  S. J. Beur,et al.  Tumor-Induced Osteomalacia , 2005 .

[28]  E. Montgomery,et al.  Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic Entity: An Analysis of 32 Cases and a Comprehensive Review of the Literature , 2004, The American journal of surgical pathology.